OncoMatch/Clinical Trials/NCT04472767
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Is NCT04472767 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Ipilimumab for hepatocellular carcinoma.
Treatment: Nivolumab · Ipilimumab · Cabozantinib — This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic anti-cancer treatment
Any type of previous systemic anti-cancer treatment
Cannot have received: cabozantinib (cabozantinib)
Prior treatment with cabozantinib
Cannot have received: cytotoxic, biologic or other systemic anticancer therapy including investigational agents
Has received prior cytotoxic, biologic or other systemic anticancer therapy including investigational agents within 4 weeks prior to randomization
Cannot have received: small molecule kinase inhibitor
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Lab requirements
Blood counts
Leukocytes ≥ 2,000/mcL; absolute neutrophil count ≥ 1000/mcL; platelets ≥ 60,000/mcl; hemoglobin ≥ 8 g/dL
Kidney function
creatinine <1.5ULN; Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg
Liver function
total bilirubin within normal institutional limits; AST(SGOT)/ALT(SPGT) ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present; Serum albumin ≥ 2.8 g/dL
Cardiac function
Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment
Adequate organ and marrow function as defined below: Leukocytes ≥ 2,000/mcL; absolute neutrophil count ≥ 1000/mcL; platelets ≥ 60,000/mcl; total bilirubin within normal institutional limits; AST(SGOT)/ALT(SPGT) ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present; creatinine <1.5ULN; hemoglobin ≥ 8 g/dL; Serum albumin ≥ 2.8 g/dL; Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg; Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04472767 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages